Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

45.47 +0.35 (+0.78%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,179,807
Open 45.00
Bid (Size) 45.46 (1,200)
Ask (Size) 45.47 (7,300)
Prev. Close 45.12
Today's Range 44.97 - 45.68
52wk Range 29.66 - 46.14
Shares Outstanding 388,132,400
Dividend Yield 1.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key... 
Via StockStory
Topics Earnings

Performance

YTD
+17.0%
+17.0%
1 Month
+12.5%
+12.5%
3 Month
+14.4%
+14.4%
6 Month
+26.3%
+26.3%
1 Year
+34.5%
+34.5%

More News

Read More
News headline image
Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗
Via The Motley Fool
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗
Via Chartmill
Why Is TEVA Stock Rising Pre-Market Today? ↗
Via Stocktwits
News headline image
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Bonds
News headline image
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Via StockStory
News headline image
Royalty Pharma Reports Q4 and Full Year 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
Via StockStory
Topics World Trade
News headline image
3 Mid-Cap Stocks We Keep Off Our Radar
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Via StockStory
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Overrated Stocks We Steer Clear Of
Via StockStory
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks We’re Skeptical Of
Via StockStory
Topics Stocks
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗
Via Chartmill
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 45.47
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 02/23/26 04:00 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 17.65B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.